{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T01:06:16Z","timestamp":1785546376940,"version":"3.56.0"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circ: Cardiovascular Quality and Outcomes"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Clinical practice guidelines recommend routine kidney function and serum potassium testing within 30 days of initiating ACE (angiotensin-converting enzyme) inhibitor or angiotensin II receptor blocker therapy. However, evidence is lacking about whether follow-up testing reduces therapy-related adverse outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods and Results:<\/jats:title>\n            <jats:p>We conducted 2 population-based retrospective cohort studies in Kaiser Permanente Northern California and Ontario, Canada. Patients with outpatient serum creatinine and potassium tests in the 30 days after starting ACE inhibitor or angiotensin II receptor blocker therapy were matched 1:1 to patients without follow-up tests. We evaluated the association of follow-up testing with 30-day all-cause mortality and hospitalization with acute kidney injury or hyperkalemia using Cox regression. We also developed and externally validated a risk score to identify patients at risk of having abnormally high serum creatinine and potassium values in follow-up. We identified 75 251 matched pairs initiating ACE inhibitor or angiotensin II receptor blocker therapy between January 1, 2007, and December 31, 2017, in Kaiser Permanente Northern California. Follow-up testing was not significantly associated with 30-day all-cause mortality in Kaiser Permanente Northern California (hazard ratio, 0.75 [95% CI, 0.54\u20131.06]) and was associated with higher mortality in 84 905 matched pairs in Ontario (hazard ratio, 1.32 [95% CI, 1.07\u20131.62]). In Kaiser Permanente Northern California, follow-up testing was significantly associated with higher rates of hospitalization with acute kidney injury (hazard ratio, 1.66 [95% CI, 1.10\u20132.22]) and hyperkalemia (hazard ratio, 3.36 [95% CI, 1.08\u201310.41]), as was observed in Ontario. The risk score for abnormal potassium provided good discrimination (area under the curve [AUC], 0.75) and excellent calibration of predicted risks, while the risk score for abnormal serum creatinine provided moderate discrimination (AUC, 0.62) but excellent calibration.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Routine laboratory monitoring after ACE inhibitor or angiotensin II receptor blocker initiation was not associated with a lower risk of 30-day mortality. We identified patient subgroups in which targeted testing may be effective in identifying therapy-related changes in serum potassium or kidney function.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1161\/circoutcomes.119.006415","type":"journal-article","created":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T09:00:23Z","timestamp":1599037223000},"update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":13,"title":["Kidney Function and Potassium Monitoring After Initiation of Renin-Angiotensin-Aldosterone System Blockade Therapy and Outcomes in 2 North American Populations"],"prefix":"10.1161","volume":"13","author":[{"given":"Rishi V.","family":"Parikh","sequence":"first","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California, Oakland (R.V.P., T.C.T., F.K.-R., A.S.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4593-3675","authenticated-orcid":true,"given":"Danielle M.","family":"Nash","sequence":"additional","affiliation":[{"name":"ICES, Ontario, Canada (D.M.N., E.M., M.M.S., A.X.G.)."},{"name":"Department of Health Research Methods, Evidence, and Impact (D.M.N., M.M.-R., A.X.G.), McMaster University, Hamilton, Ontario, Canada."},{"name":"Ontario Renal Network, Toronto, Canada (D.M.N., G.E.N., A.X.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Scott","family":"Brimble","sequence":"additional","affiliation":[{"name":"Department of Medicine (K.S.B.), McMaster University, Hamilton, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Markle-Reid","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence, and Impact (D.M.N., M.M.-R., A.X.G.), McMaster University, Hamilton, Ontario, Canada."},{"name":"School of Nursing (M.M.-R.), McMaster University, Hamilton, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thida C.","family":"Tan","sequence":"additional","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California, Oakland (R.V.P., T.C.T., F.K.-R., A.S.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"McArthur","sequence":"additional","affiliation":[{"name":"ICES, Ontario, Canada (D.M.N., E.M., M.M.S., A.X.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzien","family":"Khoshniat-Rad","sequence":"additional","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California, Oakland (R.V.P., T.C.T., F.K.-R., A.S.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish M.","family":"Sood","sequence":"additional","affiliation":[{"name":"ICES, Ontario, Canada (D.M.N., E.M., M.M.S., A.X.G.)."},{"name":"Division of Nephrology, University of Ottawa, Ontario, Canada (M.M.S.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijie","family":"Zheng","sequence":"additional","affiliation":[{"name":"Nephrology Service Line, The Permanente Medical Group (S.Z., L.P.)."},{"name":"Department of Nephrology, Kaiser Permanente Oakland Medical Center, CA (S.Z., L.P.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonid","family":"Pravoverov","sequence":"additional","affiliation":[{"name":"Nephrology Service Line, The Permanente Medical Group (S.Z., L.P.)."},{"name":"Department of Nephrology, Kaiser Permanente Oakland Medical Center, CA (S.Z., L.P.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gihad E.","family":"Nesrallah","sequence":"additional","affiliation":[{"name":"Ontario Renal Network, Toronto, Canada (D.M.N., G.E.N., A.X.G.)."},{"name":"Humber River Hospital, Toronto, Ontario, Canada (G.E.N.)."},{"name":"Department of Medicine, University of Toronto, Ontario, Canada (G.E.N.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit X.","family":"Garg","sequence":"additional","affiliation":[{"name":"ICES, Ontario, Canada (D.M.N., E.M., M.M.S., A.X.G.)."},{"name":"Department of Health Research Methods, Evidence, and Impact (D.M.N., M.M.-R., A.X.G.), McMaster University, Hamilton, Ontario, Canada."},{"name":"Ontario Renal Network, Toronto, Canada (D.M.N., G.E.N., A.X.G.)."},{"name":"Department of Medicine, Western University, London, Ontario, Canada (A.X.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan S.","family":"Go","sequence":"additional","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California, Oakland (R.V.P., T.C.T., F.K.-R., A.S.G.)."},{"name":"Departments of Epidemiology (A.S.G.)"},{"name":"Biostatistics (A.S.G.)"},{"name":"Medicine (A.S.G.)"},{"name":"University of California, San Francisco (A.S.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2015.10.011"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-5922.2010.00258.x"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.116.07363"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/hpu209"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2013.04.018"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw129"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j791"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.01730215"},{"key":"e_1_3_3_10_2","first-page":"1","article-title":"KDIGO 2012 Clinical practice guideline for the evaluation and management of chronic kidney disease.","volume":"3","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2013","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1\u2013150","journal-title":"Kidney Int Suppl"},{"key":"e_1_3_3_11_2","volume-title":"Chronic Kidney Disease (Partial Update): Early Identification and Management of Chronic Kidney Disease in Adults in Primary and Secondary Care","author":"National Clinical Guideline Centre (UK)","year":"2014","unstructured":"National Clinical Guideline Centre (UK). Chronic Kidney Disease (Partial Update): Early Identification and Management of Chronic Kidney Disease in Adults in Primary and Secondary Care. London: National Institute for Health and Care Excellence (UK); 2014. (NICE Clinical Guidelines, No. 182). https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK248058\/"},{"key":"e_1_3_3_12_2","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease.","volume":"43","author":"Kidney Disease Outcomes Quality Initiative (K\/DOQI)","year":"2004","unstructured":"Kidney Disease Outcomes Quality Initiative (K\/DOQI). K\/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43:5 suppl 1S1\u2013290","journal-title":"Am J Kidney Dis"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-014-0160-0"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1217"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-012818"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-009-1228-x"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1935"},{"key":"e_1_3_3_18_2","unstructured":"Gordon NP. Characteristics of Adult Health Plan Members in the Northern California Region Membership as Estimated from the 2011 Member Health Survey. 2013. https:\/\/divisionofresearch.kaiserpermanente.org\/projects\/memberhealthsurvey\/SiteCollectionDocuments\/mhs11reg.pdf. Accessed May 1 2017"},{"key":"e_1_3_3_19_2","unstructured":"Ontario Ministry of Finance. 2016 Census Highlights: Factsheet 3. 2017. https:\/\/www.fin.gov.on.ca\/en\/economy\/demographics\/census\/cenhi16-3.html. Accessed June 17 2018"},{"key":"e_1_3_3_20_2","unstructured":"Ontario Ministry of Health & Long-term Care. Ontario Public Drug Programs. 2016. http:\/\/www.health.gov.on.ca\/en\/public\/programs\/drugs\/. Accessed July 8 2016"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2010.02.337"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2016.09.038"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12109"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.5.685"},{"key":"e_1_3_3_25_2","first-page":"1","article-title":"KDIGO clinical practice guideline for acute kidney injury.","volume":"2","author":"KDIGO AKI Work Group","year":"2012","unstructured":"KDIGO AKI Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2:1\u2013138","journal-title":"Kidney Int Suppl"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.108.801654"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.13063\/2327-9214.1049"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.2105\/ajph.74.12.1324"},{"key":"e_1_3_3_29_2","first-page":"67","article-title":"Coding accuracy of administrative drug claims in the ontario drug benefit database.","volume":"10","author":"Levy AR","year":"2003","unstructured":"Levy, AR, O\u2019Brien, BJ, Sellors, C, Grootendorst, P, Willison, D. Coding accuracy of administrative drug claims in the ontario drug benefit database. Can J Clin Pharmacol. 2003;10:67\u201371","journal-title":"Can J Clin Pharmacol"},{"key":"e_1_3_3_30_2","unstructured":"The Johns Hopkins University Bloomberg School of Public Health Health Services Research & Development Center. The Johns Hopkins ACG\u00a9 Case-Mix System Version 10.0 Release Notes. 2011. https:\/\/www.healthpartners.com\/ucm\/groups\/public\/@hp\/@public\/documents\/documents\/dev_057914.pdf Accessed October 1 2018."},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0b013e3181a663cc"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1080\/00273171.2011.568786"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3697"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1198\/0003130043277"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.005428"}],"container-title":["Circulation: Cardiovascular Quality and Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/CIRCOUTCOMES.119.006415","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T03:47:18Z","timestamp":1715572038000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCOUTCOMES.119.006415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["10.1161\/CIRCOUTCOMES.119.006415"],"URL":"https:\/\/doi.org\/10.1161\/circoutcomes.119.006415","relation":{},"ISSN":["1941-7713","1941-7705"],"issn-type":[{"value":"1941-7713","type":"print"},{"value":"1941-7705","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"2019-12-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e006415"}}